Revenue + Forward P/E
Alamar Biosciences, Inc. (ALMR) quarterly revenue and forward P/E
RevenueRevenue (est)Forward P/E
Valuation
Market cap
$2.34B
Enterprise value
$2.45B
P/E ratio (TTM)
-69.00x
P/S ratio (TTM)
45.70x
P/B ratio
41.60x
EV/Sales
44.23x
EV/EBITDA
-74.33x
Dividend yield
0.00%
Income statement (TTM)
Revenue (TTM)
$74.21M
Gross profit (TTM)
$41.70M
Operating income (TTM)
$-31.33M
EBITDA (TTM)
$-24.89M
Net income (TTM)
$-29.82M
Free cash flow (TTM)
$-59.99M
Margins & returns
Gross margin
58.01%
Operating margin
-46.66%
Profit margin
-62.25%
Return on equity
428.55%
Return on assets
-8.83%
Per-share metrics
EPS (TTM)
-$0.10
Dividend yield
0.00%
Beta
-6.18
Capital structure
Cash & equivalents
$30.00M
Total debt
$41.47M
Net debt
$11.47M
Shares outstanding
69.31M
Financial health
Current ratio
3.99
Debt / equity
-0.26
Debt / assets
0.30
Interest coverage
-78.14
| Company | Market cap | P/E | P/S | EV/EBITDA | Div yield |
|---|---|---|---|---|---|
| $1.15T | 42.41x | 15.59x | 34.80x | 0.54% | |
| $629.92B | 30.45x | 6.47x | 20.76x | 1.99% | |
| $442.26B | 127.13x | 7.29x | 30.82x | 2.63% | |
| $365.22B | 27.06x | 0.85x | 16.46x | 2.13% | |
| $355.30B | 23.91x | 4.80x | 15.14x | 2.67% | |
| $332.86B | 36.82x | 4.94x | 19.57x | 2.56% | |
| $2.34B | -69.00x | 45.70x | -74.33x | - |